<code id='BB05235460'></code><style id='BB05235460'></style>
    • <acronym id='BB05235460'></acronym>
      <center id='BB05235460'><center id='BB05235460'><tfoot id='BB05235460'></tfoot></center><abbr id='BB05235460'><dir id='BB05235460'><tfoot id='BB05235460'></tfoot><noframes id='BB05235460'>

    • <optgroup id='BB05235460'><strike id='BB05235460'><sup id='BB05235460'></sup></strike><code id='BB05235460'></code></optgroup>
        1. <b id='BB05235460'><label id='BB05235460'><select id='BB05235460'><dt id='BB05235460'><span id='BB05235460'></span></dt></select></label></b><u id='BB05235460'></u>
          <i id='BB05235460'><strike id='BB05235460'><tt id='BB05235460'><pre id='BB05235460'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:knowledge    Page View:8252
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In